baber/WOPTO huggingface dataset:
Patent NZ-501697-A (NZ)
Title: Teleservices workstation with integrated presentation of concurrent interactions with multiple terminal emulations, hypermedia and telephony systems
Inventor: BRENEMAN REED B
IPC: G06Q10/02
Filed: 1998-06-11
Abstract: A teleservices system, workstation configuration, and teleservices manager application provide for integrated concurrent interactions with various host computer systems, an automatic call management system, and Internet/intranet servers. The teleservices system includes an automatic call distributor and call management system, a customer database system, and various host systems providing terminal emulation based access, a hypermedia server with hypermedia data on multiple properties, host computer systems, or business locations. The teleservices workstation configuration includes a telephone server application that interfaces to the call management system, a patron server program that interfaces to the customer database system, and a configuration database that stores configuration for configuring each agent's workstation to access various ones of the host computer systems, and identifying various ones of the properties for which the agent provides services. The teleservices workstation manager application controls and interfaces with the telephone server program, the patron server program, and the configuration database. Among other functions, the teleservices workstation manager automatically retrieves customer data from the customer database in response to receiving a telephone number for an incoming telephone call, automatically configures itself to provide terminal emulation sessions for various ones of the host computer systems and properties that the agent is authorized to service, and dynamically selects and retrieves hypermedia data for various ones of such properties. The various data sources are presented through an integrated user interface, and the agent is able to efficiently transfer information between the various systems.
Patent NZ-508968-A (NZ)
Title: Genes coding for tomato beta-galactosidase II polypeptides
Inventor: GROSS KENNETH C
IPC: C12N15/09
Filed: 1999-06-08
Abstract: An isolated nucleic acid comprises a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from: (a) a nucleotide sequence encoding the beta-galactosidase II polypeptide having the complete amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16 and designated TBG1, TBG2, TBG3, TBG4, TBG5, TBG6 and TBG7, respectively as shown in Figure 2 or as encoded by the cDNA clone selected from the group consisting of cDNA clones contained in Gen Bank Accession No. AF023847, AF154420, AF154421, AF020390, AF154423, AF154424 and AF154422; (b) a nucleotide sequence encoding the mature beta- galactosidase II polypeptide having the amino acid sequence at about positions 24-724 selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16 and designated TBG1, TBG2, TBG3, TBG4, TBG5, TBG6 and TBG7, respectively as shown in Figure 2 or as encoded by the cDNA clone selected from the group consisting of cDNA clones contained in Gen Bank Accession No. AF023847, AF154420, AF154421, AF020390, AF154423, AF154424 and AF154422; or (c) a nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b), above. An isolated beta-galactosidase II polypeptide comprises an amino acid sequence at least 95% identical to a sequence selected from: (a) an amino acid sequence at about positions 24-724 selected from the group consisting of sequences SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16 and designated TBG1, TBG2, TBG3, TBG4, TBG5, TBG6 and TBG7, respectively as shown in Figure 2; or (b) an amino acid sequence as encoded by the cDNA clone selected from the group consisting of cDNA clones contained in Gen Bank Accession No. AF023847, AF154420, AF154421, AF020390, AF154423, AF154424 and AF154422. Also described are vectors comprising the nucleic acid molecule and recombinant non-human cell, plants, cells and seeds transformed with the nucleic acid and methods of modifying cell wall metabolism in a plant.
Patent NZ-510070-A (NZ)
Title: Crystalline forms of EtO2 C-CH2 -(R)Cgl-Aze-Pab-OH
Inventor: EDVARDSSON DANIEL
IPC: A61P7/02
Filed: 1999-09-02
Abstract: EtO2C-CH2-(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C-CH2-(R)Cgl-Aze-Pab-OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
Patent NZ-510156-A (NZ)
Title: Transmission of GSM circuit-switched data over a CDMA link
Inventor: SHINDELMAN DROR
IPC: H04J13/00
Filed: 1999-08-27
Abstract: In a GSM mobile wireless telecommunications system (20), a method for conveying data from terminal equipment (46) to a network (48) via a CDMA air interface, including receiving the data as input from the terminal equipment (46) and transmitting the data at a CDMA data transfer rate over the CDMA air interface. The data are transferred to the network (48) over a GSM A-interface using a GSM circuit switched data protocol.
Patent NZ-511562-A (NZ)
Title: Method for preparing a protein composition and an infant formula containing same
Inventor: JOST ROLF
IPC: A23C9/142
Filed: 1999-11-17
Abstract: A process for the manufacture of an infant formula predominately based on a lactic raw material derived from whey whose amino acid composition is similar to that of human milk comprises micro-filtrating animal milk, which has not been subjected to a heat treatment or has been subjected to pasteurization on a membrane of porosity of 0.1-0.2 microns. The permeate is concentrated and then demineralized by electrodialysis without the use of ion- exchange decationization to obtain a protein composition and casein in the microfiltration retentate, acid casein or caseinate fat and where appropriate minerals and trace elements are added to the protein composition.
Patent NZ-512351-A (NZ)
Title: A laundry appliance with load balancing system
Inventor: COLLECUTT GREGORY RAYMOND
IPC: D06F23/00
Filed: 1999-12-21
Abstract: A laundry appliance comprising a perforated rotatable drum (11) for dehydrating a clothes load, a substantially rigid, free standing drum support means supporting the drum (11) rotatably but non-translatably in relation to a support surface, driving means (39, 40) for rotating the drum (11) at speed thereby dehydrating the load, and a system for compensating for imbalances of the drum (11) and any load carried therein during dehydration of the load.
Patent NZ-516678-A (NZ)
Title: Regulation system of expression using nuclear PPAR receptors
Inventor: DARTEIL RAPHAEL
IPC: A61K35/76
Filed: 2000-06-22
Abstract: Methods and compositions for the pharmacological regulation of the expression of transgenes. A composition comprising: (a) a first element comprising a nucleic acid of interest under the control of an inducible promoter comprising an element containing a response element to a Peroxisome Proliferator-Activated Receptor (PPAR) and a minimal transcriptional receptor; and (b) a second element comprising a nucleic acid coding for a PPAR under the control of a transcriptional promoter, for simultaneous, separate or prolonged use And the use of said compositions and methods in the experimental, clinical, therapeutic or diagnostic fields.
Patent NZ-517920-A (NZ)
Title: Delayed release antibiotic preparations including a surfactant
Inventor: VOGT SEBASTIAN
IPC: A61L27/54
Filed: 2002-03-21
Abstract: Process of manufacturing a delayed-release antibiotics preparation to treat local microbial infections.  Said process involves mixing an amphiphilic component selected from various sulfates, an antibiotic component, an organic auxiliary component and/or an inorganic auxiliary component.
Patent NZ-523242-A (NZ)
Title: Phenylpyridazine derivatives and drugs containing the same
Inventor: KUMAI NATSUYO
IPC: C07D237/12
Filed: 2001-07-06
Abstract: Phenylpyridazine compounds of formula (I), salts thereof and drugs containing the compounds or the salts are disclosed, wherein R1 is optionally substituted phenyl, pyridyl, or the like; R2 is lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, or the like; R3 is hydrogen, lower alkoxy, or the like; and R4 is hydrogen, substituted alkyl, or the like]. These compounds exhibit an excellent interleukin 1b production inhibiting activity and are useful as preventive and therapeutic drugs for immunologic diseases, inflammatory diseases, ischemic disease, and so on.
Patent NZ-523783-A (NZ)
Title: Powdered product containing a high level of monoglyceride, an active lipase and optionally lecithin to aid anti-staling in bread making
Inventor: SOE JORN BORCH
IPC: A23L27/60
Filed: 2001-08-02
Abstract: An enzymatic solid phase reaction for preparing a solid having greater than 40% monoglyceride from a reaction mixture; wherein the reaction mixture comprises: (i) lipase; (ii) at least 14 weight% glycerol; and (iii) glyceride; and optionally (iv) lecithin; such that if (iv) is not present then the glyceride (iii) has an iodine value of between about 5 and about 35, and a solid fat content of more than about 75% at 20C. Further described is a process of preparing an enzymatic solid phase reaction mixture for preparing a solid having greater than 40% monoglyceride.
Patent NZ-525302-A (NZ)
Title: Provision of an insulin growth factor binding protein (IGFBP) and vitronectin-containing complex for modulating cell proliferation
Inventor: UPTON ZEE
IPC: A61L27/00
Filed: 2001-09-24
Abstract: An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided is the use of the protein complex in the manufacture of a medicament for modulating cell proliferation and/or migration for purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and/or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.
Patent NZ-526499-A (NZ)
Title: Flotation machine
Inventor: BOURKE PETER
IPC: C02F1/24
Filed: 2001-12-11
Abstract: The invention relates to a flotation machine which at least contains a flotation cell having a means for feeding slurry in the flotation cell, a means for feeding air into the slurry and producing froth, a means for removing froth from the flotation cell and a means for removing tailings from the flotation cell. According to the invention the flotation cell (1,21) is provided with at least one rotating froth removal device (6,26) immersed at least partly in the froth (9,27) and so shaped that one end of the froth removal device (8,26) is extendible over the launder (12) attached to the flotation cell (1) in order to recover the froth (9,27) from the flotation cell (1,21) using the centrifugal force generated by the froth removal device (8,26).
Patent NZ-526580-A (NZ)
Title: Quinuclidine carbamate derivatives and their use as M3 antagonists
Inventor: BUIL ALBERO MARIA ANTONIA
IPC: A61P11/00
Filed: 2001-12-20
Abstract: A compound which is a carbamate of formula (I) and a pharmaceutically acceptable salt thereof is disclosed, wherein R1 represents substituents of formulae (a), (b), (c), (d), (e), (f), (g), (h) or (i); R2 represents a benzyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl or thiophen-3-ylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbons atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p is 1 or 2 and the substitution in the azabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; and R3 represents a hydrogen or halogen atom, or a straight or branched lower alkyl group or a cyano group. The pharmaceutically acceptable salt of the said compound may be of formula (II).
Patent NZ-534195-A (NZ)
Title: Elastomer-modified epoxy siloxane compositions suitable for protective coatings
Inventor: HARUJI SAKUGAWA
IPC: C08L63/00
Filed: 2003-01-29
Abstract: Elastomer-modified epoxy-polysiloxane compositions that are prepared by combining a silicone intermediate of formula (I) (wherein R1, R2 and n are as defined in the specification), with an epoxy resin, an elastomeric resinous intermediate, a polyfunctional amine (such as an aminosilane of formula: Y-Si-(O-X)3, wherein Y and X are as defined in the specification), an optional organometallic catalyst, and optional fillers, pigments, and processing agents are disclosed. The composition is prepared using a sufficient amount of water to promote hydrolysis of the polysiloxane and the polycondensation of the silanols produced by such hydrolysis. In its cured form, the epoxy-polysiloxane composition exists as a uniformly dispersed arrangement of linear epoxy chain fragments that are cross-linked with a continuous polysiloxane polymer chain, wherein either or both of the epoxy and/or polysiloxane polymers are elastomer modified to provide coatings and floorings having significantly improved properties of impact resistance, flexibility, crack resistance, and abrasion resistance with compared to conventional epoxy systems.
Patent NZ-534930-A (NZ)
Title: Methods of detecting and quantifying nucleic acid binding factors and coregulators thereof based upon proximity-based luminescence transfer
Inventor: HEYDUK TOMASZ
IPC: C12Q1/68
Filed: 2003-01-23
Abstract: Described are biosensors and methods to determine the activity of any and all nucleic acid binding factors, proteins, cellular events, nucleic acid binding protein coregulators, or fragments thereof, based upon the stabilisation of the interaction of two nucleic acid components, which together comprise a complete nucleic acid binding element, by the binding of a nucleic acid binding factor are provided. Preferably, a fluorescence donor is attached to a nucleic acid comprising one portion or component of a complete nucleic acid binding element and a fluorescence acceptor is attached to a nucleic acid comprising the other portion or component of the same complete binding element. Alternatively, a solid substrate is attached to a nucleic acid comprising one portion of a binding element and a detectable label is attached to a nucleic acid comprising the other portion of the same binding element. Binding of a nucleic acid binding factor to the nucleic acid components affects a change in luminescence or the association of the detectable label with the solid substrate. These biosensors and methods may also be used to detect mediating nucleic acid binding factor coregulators, post-translational modifications and cellular events, to diagnose diseases and/or screen for drugs or other ligands that mediate the activity of nucleic acid binding factors.
Patent NZ-536796-A (NZ)
Title: Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
Inventor: COCHRANE CHARLES G
IPC: A61K38/08
Filed: 2003-04-25
Abstract: Disclosed are compositions for treating pulmonary conditions. The compositions include at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant that is active during inflammation.
Patent NZ-540549-A (NZ)
Title: Sequence specific DNA recombination in eukaryotic cells
Inventor: DROGE PETER
IPC: C12N15/90
Filed: 2003-11-28
Abstract: A method of sequence-specific recombination of DNA in eukaryotic cells, comprising introducing of a first DNA comprising an attB, attP, attL or attR, comprising introducing a second DNA comprising attB, attP, attL or attR and performing the sequence specific recombination by a bacteriophage lambda integrase Int.
Patent NZ-544845-A (NZ)
Title: Dual universal integrated circuit card (UICC) system for a portable device
Inventor: HO CHUN-HSIN
IPC: H04W92/08
Filed: 2006-01-20
Abstract: The dual universal integrated circuit card (UICC) system for a portable device; the portable device includes a cellular phone or a personal digital assistance. The system comprises a slaver integrated circuit card having a first integrated circuit and an opening; a substrate is carrying a master integrated circuit card having a second integrated circuit and a contact interface; the contact interface is coupled to a first and second integrated circuits and an antenna is coupled to the second integrated circuit for transmitting information.
Patent NZ-548128-A (NZ)
Title: Novel 2-heteroaryl-substituted benzimidazole derivative
Inventor: NONOSHITA KATSUMASA
IPC: A61K31/4709
Filed: 2004-12-28
Abstract: Disclosed is a compound of formula (I-0) or a pharmaceutically acceptable salt thereof, wherein X represents a carbon atom or a nitrogen atom; X1, X2, X3 and X4 each independently represent a carbon atom; and wherein the rest of the substituents are disclosed within the specification. Also disclosed is the use of a compound of formula (I-0) in the preparation for treating type 2 diabetes or for treating obesity.
Patent NZ-548936-A (NZ)
Title: Selective oxidation of LL-F28249-alpha using o-iodoxybenzoic acid
Inventor: SAPIENZA STEFANIA
Filed: 2006-08-04
Abstract: A process for the selective oxidation of a 5-O-protected-LL-F28249-á compound of formula (II) wherein R is a protecting group, used in the manufacture of moxidectin.
Patent NZ-548960-A (NZ)
Title: Emergency alert system
Inventor: RODING WERNHER ERICH
Filed: 2006-08-04
Abstract: An emergency alert device, for use in providing an alert in the event of an emergency or other notifiable event, is disclosed. The device includes a ripple control receiver means that is configured and arranged to receive, in use, a ripple control signal. The ripple control signal is fed through the mains power supply from an electrical power grid to an alert indicator means, which is located either remotely from the device or electrically connected to the device. The alert indicator means is configured to provide an output alert signal in response to the received ripple control signal.
Patent NZ-549911-A (NZ)
Title: Improvements in or relating to SIFT-MS instruments
Inventor: WILSON PAUL FRANCIS
Filed: 2006-10-19
Abstract: A method of improving the signal intensity of the precursor ions constrained in a carrier gas in the flow tube of a SIFT-MS instrument comprises the application of an electrical potential to the flow tube to lower the diffusive loss of ions within the flow tube. Also disclosed is a SIFT-MS (selected ion flow ass spectrometry) instrument having a flow tube and including a means to provide an electrical potential to the flow tube to lower the diffusive loos of ions within the flow tube.
Patent NZ-551620-A (NZ)
Title: Aircraft beacon device on wind power installations
Inventor: WOBBEN ALOYS
IPC: F03D11/00
Filed: 2001-05-08
Abstract: A flight warning light arrangement for mounting on a wind turbine tower includes a flight warning light 10 and a transportable energy source. A transportation container 20 for transportation of the energy source includes an intermediate energy storage element 26 that is adapted to be fed electrical energy from an energy producing element that is at least one of a wind generator 28 or a photovoltaic module 29. A charge regulator 30 is connected between the intermediate energy storage element and the energy producing element. The arrangement also includes a device 24 for detecting the ambient brightness around the arrangement and a switching device 22 for evaluating the detected brightness value and switching on the warning light when the brightness value is detected as less than a given value. When the arrangement is installed on the tower, the energy producing element is fixed either to the top of the transportation container or to an appropriate location at the top of the tower.
Patent NZ-553177-A (NZ)
Title: Potting process for potting porous hollow filtration membranes to make membrane filtration modules
Inventor: KEDZIORA EUGENE
IPC: B01D63/02
Filed: 2005-08-23
Abstract: A process for potting porous hollow membranes (5) is disclosed. The process includes the steps of: a) providing a potting mould (6) having details (8) formed in its surface to allow cooperation with components having elements for mounting the membranes (5) and elements for fluid communication with the membranes (5), where the details (8) are formed by potting material (9) which takes a negative shape of the potting mould (6) and where the shape corresponds to details (8) of a potting sleeve; b) positioning ends of the membranes (5) in the mould (6); c) filling the mould (6) with potting material (9); d) allowing the potting material (9) to at least partially cure; and e) removing pot formed from the potting material (9) from the mould (6).
Patent NZ-566705-A (NZ)
Title: Compositions and methods for preparation of poorly water soluble drugs with increased stability
Inventor: DESAI NEIL P
IPC: A61K9/00
Filed: 2006-08-30
Abstract: Disclosed is a pharmaceutical composition comprising nanoparticles comprising docetaxel, wherein the docetaxel used for preparation of the composition is in an anhydrous form. Also disclosed is the use of said composition for the treatment of cancer and a method to prepare said compound.
Patent NZ-572886-A (NZ)
Title: Means and method for inducing exon-skipping
Inventor: AARTSMA-RUS ANNEMIEKE
IPC: A61K31/7115
Filed: 2007-05-18
Abstract: Provided is a method for determining whether the efficiency can be increased with which a dystrophin exon is excluded from a mature dystrophin mRNA in a cell that produces an exon containing precursor of said mRNA said method comprising providing said cell with a first anti-sense oligonucleotide (AON) that can hybridise to an exon internal part of said exon, and determining whether said efficiency is increased upon providing said cell with a second AON that can hybridise to another exon internal part of said exon, wherein said dystrophin exon is exon 45. The method is useful in regulating aberrant proteins in cells, including tumor cells.
Patent NZ-578597-A (NZ)
Title: Methods of processing a transmission and generating a data frame for transmision within a wireless network
Inventor: QUICK MARIE
IPC: H04L47/32
Filed: 2008-02-06
Abstract: A method of processing a transmission within a wireless network and a method of generating a data frame for transmission in a wireless communications network is disclosed. The network includes at least one transmitting device to transmit the transmission and at least one receiving device to receive the transmission. The method of processing the transmission within a wireless network comprises: (a) receiving the transmission at the receiving device; (b) determining a transmission signature for the transmission based upon the product of an originating transmitter identifier, identifying an originating transmitter, and a transmission identifier included in the received transmission; (c) comparing the determined transmission signature with one or more stored transmission signatures of previous transmissions stored in a memory of the receiving device to determine whether the receiving device has previously received the transmission; and (d) actioning the received transmission and storing the transmission signature in the memory of the receiving device only if the receiving device has not previously received the transmission.